Aktis Oncology (AKTS US) delivered a strong debut to kick off the 2026 IPO market, marking a clear win for both new issuance and the biotech sector. The deal was upsized to 17.65 million shares ahead of pricing, ultimately pricing at the top of the range at $18.00. Shares opened at $27.00, representing an immediate 50% gain, and traded as high as $29.16 within the first five minutes of trading. While the stock experienced steady selling pressure throughout the session, it found support, traded as low as $19.33, and ultimately closed at $22.40, delivering a +24% first-day return. The performance represents a decisive and confidence-boosting start to the IPO calendar.
The strong reception was driven by a combination of favorable market timing, a well-structured offering, and a high-quality investor base. Importantly, Aktis priced and debuted ahead of the highly anticipated J.P. Morgan Healthcare Conference, an unusual but telling signal of confidence from both issuers and underwriters. Channel checks leading into pricing had indicated the deal was north of ten-times oversubscribed, and demand was strong enough to support both the upsizing and pricing at the high end of the range.
Radiopharma Enthusiasm
Investor enthusiasm was underpinned by Aktis’s positioning within the targeted radiopharmaceuticals space, which is increasingly viewed as one of the most promising frontiers in oncology. The company is advancing a proprietary miniprotein radioconjugate platform, with its lead asset, [225Ac]Ac-AKY-1189, currently in a Phase 1b trial targeting Nectin-4 expressing tumors. A second program, [225Ac]Ac-AKY-2519, targeting B7-H3, is expected to enter the clinic in 2026. With over $246 million in cash prior to the IPO, the company entered the public markets with a solid balance sheet and clearly articulated use of proceeds.
A major differentiator for the offering was Aktis’s strategic collaboration with Eli Lilly, which provided meaningful third-party validation of the platform. Lilly’s involvement went beyond a traditional partnership, as the pharmaceutical giant reportedly indicated for approximately $100 million of the offering, effectively anchoring the deal and limiting available float. This cornerstone participation played a key role in stabilizing the order book and supporting aftermarket performance.
The shareholder base—including MPM BioImpact, RA Capital, EcoR1, and VV Manager II—also contributed to investor confidence. These firms are well known for backing high-quality biotech IPOs and remaining engaged post-listing.
Looking Ahead
The IPO calendar is expected to be dormant next week due to the J.P. Morgan Healthcare Conference, followed by the MLK market holiday the subsequent week. Activity should reaccelerate shortly thereafter, with issuers such as EquipmentShare.com, ARKO Petroleum, Motive Technologies, MiniMed Group, and PicS N.V. all actively in the pipeline with the potential to debut in late January or early February.